3 Very New Findings About Pneumonia
Three studies culled from the very recent literature offer insights into prevention and treatment of pneumonia in adults. Highlights in this slide show.
Three studies culled from the very recent literature offer insights into prevention and treatment of pneumonia in adults. Highlights from those studies follow. ©Puwadol-Jaturawutthichai/Shutterstock.com
A study by Postma et al in The New England Journal of Medicine compared strategies of empirical antibiotic treatment for patients with clinically suspected community-acquired pneumonia (CAP) who are admitted to non-ICU hospital wards. They compared beta-lactam monotherapy, beta-lactamâmacrolide combination therapy, and fluoroquinolone monotherapy. Beta-lactam monotherapy was inferior to the two other strategies with regard to 90-day mortality.Details here.
Bonten and colleagues investigated the efficacy of pneumococcal polysaccharide conjugate vaccines against pneumococcal community-acquired pneumonia in adults 65 years and older. Their study, published in The New England Journal of Medicine, found that in older adults, PCV13 prevented vaccine-type pneumococcal, bacteremic, and non-bacteremic community-acquired pneumonia and vaccine-type invasive pneumococcal disease-but not CAP from any cause.Details here.
Corrales-Medina and colleagues sought to determine whether hospitalization for pneumonia is associated with an increased short- and long-term risk of cardiovascular disease (CVD). Results of their study, published in JAMA, showed that hospitalization was associated with a short- and long-term risk of CVD, and suggested that pneumonia may be a risk factor for CVD.Details here.
Three studies culled from the very recent literature offer insights into prevention and treatment of pneumonia in adults. The following slides provide very brief overviews of the key findings.
